Drug Database
Back to search

France· FR:65346765

BI MISSILOR 1,5 M.U.I./250 mg, comprimé pelliculé

A medicinal product containing spiramycine + métronidazole, registered in France by PIERRE FABRE MEDICAMENT, on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedBI MISSILOR 1,5 M.U.I./250 mg, compri…ATC—REGISTER NO.FR:65346765PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about spiramycine + métronidazoleAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
SPIRAMYCINE + MÉTRONIDAZOLE
Manufacturer
PIERRE FABRE MEDICAMENT
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400937110266
    plaquette(s) PVC-Aluminium de 10 comprimé(s)
    EUR 3.72

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Spiramycine + métronidazole in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All spiramycine + métronidazole products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Bulgaria · Би-Ровамет, Ровамет
  • Spain · Metronidazol/Espiramicina Farmalider, Rhodogil

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3c2f4941-553e-4f65-9141-a10a9dbb0b27
GET /v1/drugs/3c2f4941-553e-4f65-9141-a10a9dbb0b27?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "65346765",
  "date_amm": "2005-11-24",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "SPIRAMYCINE + MÉTRONIDAZOLE",
  "statut_amm": "Autorisation active",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about spiramycine + métronidazole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console